MTOR and lung carcinoma: Notably, DHA enhanced gefitinib-induced inhibition of NCI-H1975 lung cancer cells in migration and invasion via AKT/mammalian target of rapamycin (mTOR)/STAT3 signaling pathway, and co-administration of DHA and gefitinib induced cell cycle arrest in the G2/M phase 84 (Figure 3).